References
- Smyth E , VerheijM, AllumW, CunninghamD, CervantesA, ArnoldD. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.27, v38–v49 (2016).
- Servier data on file. Advisory board meeting minutes. (2019).
- Shitara K , DoiT, DvorkinMet al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol.19(11), 1437–1448 (2018).
- Li J , QinS, XuJ, XiongJ, WuC, BaiYet al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J. Clin. Oncol.34(13), 1448–1454 (2016).
- Sung H , FerlayJ, SiegelRLet al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71(3), 209–249 (2021).
- Mayer RJ , Van CutsemE, FalconeAet al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med.372(20), 1909–1919 (2015).
- Tabernero J , AlsinaM, ShitaraKet al. Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS. Gastric Cancer23(4), 689–698 (2020).
- EMA . Summary of product characteristics (SmPC): trifluridine/tipiracil (Lonsurf). (2016). www.ema.europa.eu/en/documents/product-information/lonsurf-epar-product-information_en.pdf
- Medicines & Healthcare Products Regulatory Agency . MHRA: Summary of Product Characteristics–Lonsurf 15 mg/6.14 mg film-coated tablets. (2021). https://mhraproducts4853.blob.core.windows.net/docs/43bcc3b79dd4ebf599d263e3a393f40689a6d972
- Medicines & Healthcare products Regulatory Agency . MHRA: Summary of Product Characteristics–Lonsurf 20 mg/8.19 mg film-coated tablets (2021). https://mhraproducts4853.blob.core.windows.net/docs/9ddf7b44d7c62c0e902f9bc955528c68bd8db0e0
- Medicines Advice: Trifluridine/Tipiracil (Lonsurf). Scottish Medicines Consortium, 1–13 (2021). www.scottishmedicines.org.uk/medicines-advice/trifluridinetipiracil-lonsurf-full-smc2329/
- Woods BS , SiderisE, PalmerS, LatimerN, SoaresM. Partitioned survival and state transition models for healthcare decision making in oncology: where are we now?Value Health23(12), 1613–1621 (2020).
- Bullement A , CranmerHL, ShieldsGE. A review of recent decision-analytic models used to evaluate the economic value of cancer treatments. Appl. Health Econ. Health Policy17(6), 771–780 (2019).
- Bullement A , UnderhillS, FougerayR, HatswellAJ. Cost-effectiveness of trifluridine/tipiracil for previously treated metastatic colorectal cancer in England and Wales. Clin. Colorectal Cancer17(1), e143–e151 (2018).
- Working with SMC–A Guide for Manufacturers . Scottish Medicines Consortium. (2021). www.scottishmedicines.org.uk/media/6164/working-with-smc.pdf
- PMG36: NICE Health Technology Evaluations: the Manual . National Institute for Health and Care Excellence (2022). www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation
- Latimer NR . NICE DSU Technical Support Document 14: Survival Analysis for Economic Evaluations Alongside Clinical Trials–Extrapolation with Patient-Level Data.University of Sheffield, Sheffield, UK, 1–52 (2011). http://nicedsu.org.uk/wp-content/uploads/2016/03/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf
- Aaronson NK , AhmedzaiS, BergmanBet al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl Cancer Inst.85(5), 365–376 (1993).
- Kontodimopoulos N , AletrasVH, PaliourasD, NiakasD. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. Value Health12(8), 1151–1157 (2009).
- National Health Service . Improvement 2017/18 NHS Reference Costs (2019). https://webarchive.nationalarchives.gov.uk/ukgwa/20200501111106/https:/improvement.nhs.uk/resources/reference-costs/
- Curtis L , BurnsA, Personal Social Services Research Unit. Unit Costs of Health and Social Care.University of Kent, Canterbury, Kent, UK, 1–201 (2018). www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2018/
- TA378: Ramucirumab for Treating Advanced Gastric Cancer or Gastro–oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy. National Institute for Health and Care Excellence. (2016). www.nice.org.uk/guidance/ta378/history
- Round J , JonesL, MorrisS. Estimating the cost of caring for people with cancer at the end of life: a modelling study. Palliat. Med.29(10), 899–907 (2015).
- Medicines Advice: Autologous Anti-CD19-transduced CD3+ Cells (KTE-X19) 0.4 to 2×108 Cells Dispersion for Infusion (Tecartus®). Scottish Medicines Consortium. Glasgow, UK (2021). www.scottishmedicines.org.uk/media/6180/autologous-tecartus-final-july-2021-for-website.pdf
- Thokala P , SrivastavaT, SmithRet al. Living health technology assessment: issues, challenges and opportunities. Pharmacoeconomics41(3), 227–237 (2023).
- Gourzoulidis G , KoulentakiM, KoumarianouAet al. Cost-effectiveness of trifluridine/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastrohesophageal junction, among patients previously treated in Greece. Expert Rev. Pharmacoecon. Outcomes Res.22(2), 259–269 (2022).
- Zhou K , ZhouJ, ZhangM, LiaoW, LiQ. Cost-effectiveness of trifluridine/tipiracil (TAS102) for heavily pretreated metastatic gastric cancer. Clin. Transl. Oncol.22(3), 337–343 (2020).
- Takushima Y , IgarashiA, YoshiharaH, ShitaraK, DoiT. Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan. Jpn J. Clin. Oncol.51(9), 1383–1390 (2021).